Publicaciones en colaboración con investigadores/as de Tel Aviv University (16)

2024

  1. Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM

    Journal of the American Heart Association, Vol. 13, Núm. 15, pp. e035993

  2. Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM

    Journal of the American College of Cardiology, Vol. 84, Núm. 19, pp. 1821-1831

2023

  1. Ventricular arrhythmias in patients with hypertrophic cardiomyopathy: Prevalence, distribution, predictors, and outcome

    Heart Rhythm, Vol. 20, Núm. 10, pp. 1385-1392

2022

  1. Hypokinetic hypertrophic cardiomyopathy: clinical phenotype, genetics, and prognosis

    ESC Heart Failure, Vol. 9, Núm. 4, pp. 2301-2312

2020

  1. Clinical Profile of Cardiac Involvement in Danon Disease: A Multicenter European Registry

    Circulation: Genomic and Precision Medicine, Vol. 13, Núm. 6, pp. E003117

  2. Natural History and Risk Stratification in Andersen-Tawil Syndrome Type 1

    Journal of the American College of Cardiology, Vol. 75, Núm. 15, pp. 1772-1784

  3. Reduction in Filamin C transcript is associated with arrhythmogenic cardiomyopathy in Ashkenazi Jews

    International Journal of Cardiology, Vol. 317, pp. 133-138

2019

  1. Electrophysiological abnormalities in induced pluripotent stem cell-derived cardiomyocytes generated from Duchenne muscular dystrophy patients

    Journal of Cellular and Molecular Medicine, Vol. 23, Núm. 3, pp. 2125-2135

  2. The impact of diabetes mellitus on the clinical phenotype of hypertrophic cardiomyopathy

    European Heart Journal, Vol. 40, Núm. 21, pp. 1671-1677

2018

  1. European expert consensus statement on therapeutic goals in Fabry disease

    Molecular Genetics and Metabolism, Vol. 124, Núm. 3, pp. 189-203

  2. Modeling peripartum cardiomyopathy with human induced pluripotent stem cells reveals distinctive abnormal function of cardiomyocytes

    Circulation

2016

  1. Truncating FLNC Mutations Are Associated With High-Risk Dilated and Arrhythmogenic Cardiomyopathies

    Journal of the American College of Cardiology, Vol. 68, Núm. 22, pp. 2440-2451

2015

  1. Phenotype and prognostic correlations of the converter region mutations affecting the β myosin heavy chain

    Heart, Vol. 101, Núm. 13, pp. 1047-1053

2014

  1. Merits and pitfalls of genetic testing in a hypertrophic cardiomyopathy clinic

    Israel Medical Association Journal, Vol. 16, Núm. 11, pp. 707

2012

  1. A family with recurrent sudden death and no clinical clue

    Annals of Noninvasive Electrocardiology, Vol. 17, Núm. 4, pp. 387-393

2010

  1. Genetic counselling and testing in cardiomyopathies: A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases

    European Heart Journal